See the DrugPatentWatch profile for cosentyx

There is no specific recommended vaccine timeline post Cosentyx (secukinumab) as it depends on various factors such as the patient's overall health, age, and specific medical history. However, it is generally recommended to consult with a healthcare provider to determine the best course of action.

Cosentyx is a medication used to treat several conditions including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. It is a type of drug called a monoclonal antibody, which works by targeting and blocking a specific protein in the body that causes inflammation.

When it comes to vaccinations, it is important to note that some vaccines may not be as effective when given during or shortly after treatment with Cosentyx. This is because the medication can affect the body's immune response to the vaccine.

According to DrugPatentWatch.com, Cosentyx is manufactured by Novartis and was first approved for use in the United States in 2015. The website also notes that the drug is currently available as a prescription medication and is covered by several patents, with the earliest expiration date in 2025.

In summary, while there is no specific recommended vaccine timeline post Cosentyx, it is important to consult with a healthcare provider to determine the best course of action. Patients should also be aware that some vaccines may not be as effective when given during or shortly after treatment with Cosentyx.

Sources:

* DrugPatentWatch.com. (n.d.). Cosentyx (secukinumab): Side effects, dosage, uses, and more. Retrieved from <https://www.drugpatentwatch.com/drugs/cosentyx>